Advertisement

The current status of the Stanford randomized clinical trials of the management of Hodgkin’s disease

  • S. A. Rosenberg
Chapter
Part of the Developments in Oncology book series (DION, volume 32)

Abstract

Randomized trials designed to improve the management of patients with Hodgkin’s disease were initiated at Stanford University in 1962. These studies tested different irradiation programs for patients with Clinical Stages (CS) I, II and III disease. In 1967 the study for patients with Stages IA and IIA was modified utilizing more extensive radiation fields and as of July 1968 routine diagnostic exploratory laparotomy and splenectomy.

Keywords

Pathologic Stage Combine Modality Combine Modality Therapy Involve Field Irradiation Total Lymphoid Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg SA, Kaplan HS, Hoppe RT et al. (1982). The Stanford randomized trials of the treatment of Hodgkin’s disease: 1967–1980. In: Rosenberg SA and Kaplan HS (Eds.). Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment, pp. 513–522. New York: Academic Press.Google Scholar
  2. 2.
    Kaplan ES and Meier P (1958). Non-parametric estimation from incomplete observation. Amer Stat Assoc J 53: 457–480.CrossRefGoogle Scholar
  3. 3.
    Gehan EA (1965). A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52: 203–233.PubMedGoogle Scholar
  4. 4.
    Cox DR (1972). Regression models and life tables. J Roy Stat Soc B 34: 187–220.Google Scholar
  5. 5.
    Kaplan HS (1980). Hodgkin’s Disease, 2nd ed. Cambridge, London: Harvard University Press.Google Scholar
  6. 6.
    DeVita VT Jr, Serpick AA and Carbone PP (1970). Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 75: 881–895.Google Scholar
  7. 7.
    DeVita VT Jr (1981). The consequences of the chemotherapy of Hodgkin’s disease: The 10th David A. Karnofsky Memorial Lecture. Cancer 47: 1–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Wolin EM, Rosenberg SA and Kaplan HS (1979). A randomized comparison of PAVe and MOP(P) as adjuvant chemotherapy for Hodgkin’s disease. In: Salmon SE and Jones SE (Eds). Adjuvant Therapy of Cancer. II, pp. 119–127. New York: Grune and Stratton.Google Scholar
  9. 9.
    Santoro A, Bonfante V, Bonadonna G et al. (1981). Therapeutic and toxicologic effects of MOPP vs ABVD combined with radiotherapy in Hodgkin’s disease. In: Salmon SE and Jones SE (Eds). Adjuvant Therapy of Cancer. III., pp. 85–91. New York: Grune and Stratton.Google Scholar
  10. 10.
    Santoro A, Bonadonna G, Bonfante V and Valagussa P (1982). Alternating drug combinations in the treatment of advanced Hodgkin’s disease. N Engl J Med 306: 770–775.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • S. A. Rosenberg
    • 1
  1. 1.Stanford University School of MedicineStanfordUSA

Personalised recommendations